{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-051845","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.364241+00:00","generated_at":"2026-06-05T06:33:40.130720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Karyopharm reports FY2023 total rev $146M, XPOVIO net $112M; guides 2024 total $140-160M","bullets":["Full year 2023 total revenue $146.0M (down from $157.1M YoY); net loss $143.1M ($1.25/sh) vs $165.3M loss in 2022.","Q4 2023 XPOVIO net product revenue $25.1M; full year $112.0M, down ~7% YoY due to competition and PAP utilization.","Three pivotal Phase 3 top-line readouts expected in 2025: endometrial cancer, myelofibrosis, multiple myeloma.","2024 guidance: total revenue $140-160M, XPOVIO net $100-120M, R&D+SG&A $260-280M, cash runway to late 2025.","Cash, equivalents and investments $192.4M as of Dec 31, 2023 vs $279.7M a year earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-051845","json":"https://secwatch.observer/filing/0001193125-24-051845.json","markdown":"https://secwatch.observer/filing/0001193125-24-051845.md","text":"https://secwatch.observer/filing/0001193125-24-051845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/0001193125-24-051845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/d774952d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:33:40.130720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbea31f97fe0a95f93786ca7d5e9a22aa6370da1","claim":"Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total Revenue of $146 Million. Guidance reaffirmed.","evidence_excerpt":"Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/0001193125-24-051845-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Total Revenue of $146 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}